NP_006757
[Other Products]
NCBI GenBank Nucleotide #
|
[Other Products]
UniProt Secondary Accession #
UniProt Related Accession #
Molecular Weight
225,028 Da
NCBI Official Full Name
histone acetyltransferase KAT6A isoform 1
NCBI Official Synonym Full Names
K(lysine) acetyltransferase 6A
NCBI Official Synonym Symbols
MOZ; MRD32; MYST3; MYST-3; ZNF220; RUNXBP2; ZC2HC6A [Similar Products]
NCBI Protein Information
histone acetyltransferase KAT6A
UniProt Protein Name
Histone acetyltransferase KAT6A
UniProt Synonym Protein Names
MOZ, YBF2/SAS3, SAS2 and TIP60 protein 3; MYST-3; Monocytic leukemia zinc finger protein; Runt-related transcription factor-binding protein 2; Zinc finger protein 220
UniProt Synonym Gene Names
UniProt Entry Name
KAT6A_HUMAN
NCBI Summary for HAT-3
This gene encodes a member of the MOZ, YBFR2, SAS2, TIP60 family of histone acetyltransferases. The protein is composed of a nuclear localization domain, a double C2H2 zinc finger domain that binds to acetylated histone tails, a histone acetyl-transferase domain, a glutamate/aspartate-rich region, and a serine- and methionine-rich transactivation domain. It is part of a complex that acetylates lysine-9 residues in histone 3, and in addition, it acts as a co-activator for several transcription factors. Allelic variants of this gene are associated with autosomal dominant mental retardation-32. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Apr 2015]
UniProt Comments for HAT-3
MYST3: Histone acetyltransferase that acetylates lysine residues in histone H3 and histone H4 (in vitro). Component of the MOZ/MORF complex which has a histone H3 acetyltransferase activity. May act as a transcriptional coactivator for RUNX1 and RUNX2. Chromosomal aberrations involving KAT6A may be a cause of acute myeloid leukemias. Translocation t(8;16)(p11;p13) with CREBBP; translocation t(8;22)(p11;q13) with EP300. KAT6A- CREBBP may induce leukemia by inhibiting RUNX1-mediated transcription. Inversion inv(8)(p11;q13) generates the KAT6A-NCOA2 oncogene, which consists of the N-terminal part of KAT6A and the C-terminal part of NCOA2/TIF2. KAT6A-NCOA2 binds to CREBBP and disrupts its function in transcription activation. A chromosomal aberration involving KAT6A is a cause of therapy-related myelodysplastic syndrome. Translocation t(2;8)(p23;p11.2) with ASXL2 generates a KAT6A-ASXL2 fusion protein. Belongs to the MYST (SAS/MOZ) family.
Protein type: Nucleolus; Acetyltransferase; EC 2.3.1.48; Oncoprotein
Chromosomal Location of Human Ortholog: 8p11
Cellular Component: nucleoplasm; Golgi apparatus; PML body; nucleolus; nucleosome; nucleus
Molecular Function: protein binding; histone acetyltransferase activity; DNA binding; zinc ion binding; acetyltransferase activity; transcription coactivator activity; chromatin binding; transcription factor binding
Biological Process: heart morphogenesis; nucleosome assembly; establishment and/or maintenance of chromatin architecture; protein amino acid acetylation; transcription, DNA-dependent; somatic stem cell maintenance; embryonic hemopoiesis; negative regulation of transcription factor activity; positive regulation of transcription, DNA-dependent; myeloid cell differentiation; histone acetylation; negative regulation of transcription, DNA-dependent; DNA packaging
Disease: Mental Retardation, Autosomal Dominant 32
Research Articles on HAT-3
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice. It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.
Products associated with HAT-3 peptide
Pathways associated with HAT-3 peptide
Diseases associated with HAT-3 peptide
Organs/Tissues associated with HAT-3 peptide
|